1. Kayyal-Tarabeia I, Blank M, Zick A, Agay-Shay K. Residence near industrial complex and cancer incidence:  A registry-based cohort of 1,022,637 participants with a follow-up of 21 years, Israel. Environ Res. 216(Pt 1): 114471, 2022.

2. Koganti P, Kadali VN, Manikoth Ayyathan D, Emanuelli A, Paolini B, Levy-Cohen G, Blank M. The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function. Cell Mol Life Sci. 79: 237, 1-19, 2022. 

3. Kayyal-Tarabeia I, Michael Y, Lensky IM, Blank M, Agay-Shay K. “Residential greenness and site-specific cancer: A registry based cohort of 144,427 participants with a 21-years of follow-up, Tel-Aviv district, Israel”. Environ Res. 212(Pt C): 113460, 2022.

4. Shah PA, Boutros-Suleiman S, Emanuelli A, Paolini B, Levy-Cohen G, Blank M. The Emerging Role of E3 Ubiquitin Ligase SMURF2 in the Regulation of Transcriptional Co-Repressor KAP1 in Untransformed and Cancer Cells and Tissues. Cancers. 14(7): 1607, 1-20, 2022.

5. Ilić N, Tao Y, Boutros-Suleiman S, Kadali VN, Emanuelli A, Levy-Cohen G, Blank M. SMURF2-mediated ubiquitin signaling plays an essential role in PARP1 PARylating activity, molecular interactions and functions in mammalian cells. FASEB J. 35: e21436, 1-20, 2021.

6. Manikoth Ayyathan D, Levy-Cohen G, Shubely M, Boutros-Suleiman S, Lepechkin-Zilbermintz V, Shokhen M, Albeck A, Gruzman A, Blank M. Development and characterization of SMURF2-targeting modifiers. J Enzyme Inhib Med Chem. 36(1): 401-409, 2021.

7. Blank M. Targeted Regulation of Nuclear Lamins by Ubiquitin and Ubiquitin-Like Modifiers. Cells. 9 (6): 1340, 1-14, 2020.

8. Manikoth Ayyathan D, Koganti P, Marcu-Malina V, Litmanovitch T, Trakhtenbrot L, Emanuelli A, Apel-Sarid L, Blank M. SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis. Oncogene. 39: 3396-3410, 2020. 

9. Emanuelli A, Manikoth Ayyathan D, Koganti P, Shah PA, Apel-Sarid L, Paolini B, Detroja R, Frenkel-Morgenstern M, Blank M. Altered expression and localization of tumor suppressive E3 ubiquitin ligase SMURF2 in human prostate and breast cancer. Cancers. 11(4): 556, 1-16, 2019.

10. Koganti P, Levy-Cohen G, Blank M. Smurfs in protein homeostasis, signaling and cancer. Front Oncol. 8: 295, 1-11, 2018.

11. Blank M. Emerging roles of HECT type E3 ubiquitin ligase Smurf2 in cancer. ESMO Open. 3 (Suppl 2): A101, 2018.

12. Borroni AP, Emanuelli A, Shah PA, Ilić N, Apel-Sarid L, Paolini B,  Manikoth Ayyathan D, Koganti P, Levy-Cohen G, Blank M. Smurf2 regulates stability and the autophagic-lysosomal turnover of lamin A and its disease-associated form progerin. Aging Cell. 17(2): e12732, 1-12, 2018.

13. Hausmann M, Ilic N,  Pilarczyk G, Lee J-H,  Logeswaran A, Borroni AP, Krufczik M, Theda F,  Waltrich N, Bestvater F, Hildenbrand G, Cremer C, Blank M. Challenges for super-resolution localization microscopy and biomolecular fluorescent nano-probing in cancer research. Int J Mol Sci. 18(10): 2066, 1-21, 2017.

14. Emanuelli A, Borroni AP, Apel-Sarid L, Shah PA, Manikoth Ayyathan D, Koganti P, Levy-Cohen G, Blank M. Smurf2-mediated stabilization of DNA topoisomerase IIα controls genomic integrity. Cancer Res. 77(16): 4217-4227, 2017. In cover.

14. Manikoth Ayyathan D, Ilic N, Gil-Henn H, Blank M. Generation of SMURF2 knockout human cells using the CRISPR/Cas9 system. Analytical Biochem. 531: 56-59, 2017.

16. Zou X and Blank M. Targeting p38 MAP kinase signaling in cancer through post-translational modifications. Cancer Lett. 384: 19-26, 2017.

17. Blank M. The role of E3 ubiquitin ligase Smurf2 in cancer. Eur J Cancer. 61 (Suppl 1): S73, 2016.

18. Zou X, Levy-Cohen G, Blank M. MoIecular functions of NEDD4 E3 ubiquitin ligases in cancer. Biochim Biophys Acta. 1856: 91-106, 2015.

19. Levy-Cohen G, Blank M. Functional analysis of protein ubiquitination. Analytical Biochem. 484: 37-39, 2015.

20. Meir M, Galanty Y, Kashani L, Blank M, Fernández-Ávila MJ, Andres Cruz-Garcia A, Star A, Shochot L, Thomas Y, Garrett LJ, Chamovitz D, Bodine DM, Kurz T, Huertas P, Ziv Y, Shiloh Y. The COP9 signalosome is vital for timely repair of DNA double-strand breaks. Nucleic Acids Res. 43(9): 4517-4530, 2015.

21. Zhao X, Parpart S, Takai A, Roessler S, Budhu A, Yu Z, Blank M, Zhang YE, Jia HL,Ye QH, Qin LX, Tang ZY, Thorgeirsson SS, Wang XW. Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM+ AFP+hepatocellular Carcinoma. Oncogene. 34(39): 5095-5104, 2015.

22. Blank M and Zhang YE. Smurf2 is a novel tumor suppressor gene that governs chromatin structure and genome integrity through RNF20. Cancer Res. 72 (8 Supplement): 2195, 2012.

23. Blank M, Tang Y, Yamashita M, Burkett SS, Cheng S, Zhang YE. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nature Med18(2): 227-234, 2012. In cover.

24. Lavie G, Barliya T, Mandel M, Blank M, Ron Y, Orenstein A, Livnat T, Friedman N, Weiner L, Sheves M, Weinberger D. “Competitive quenching”: a mechanisms by which perihydroxylated perylenequinone photosensitizers can prevent adverse phototoxic damage caused by verteporfin during photodynamic therapy. Photochem Photobiol. 83(5): 1270-1277, 2007.

25. Blank M and Shiloh Y. Programs for cell death: apoptosis is only one way to go. Cell Cycle6: 686-695, 2007.

26. Blank M, Lerenthal Y ,Mittelman L, Shiloh Y. Condensin I recruitment and uneven chromatin condensation precede mitotic cell death in response to DNA damage. J Cell Biol. 174: 195-206, 2006.

27. Burov SV, Iablokova TV, Dorosh M, Shkarubskaia ZP, Blank M, Epshtein N, Fridkin M. Luliberin analogues exhibiting a cytotoxic effect on tumor cells in vitro. Bioorg Khim. 32: 459-66, 2006.

28. Hazan S, Lavie G, Blank M, Mandel M, Grunbaum A, Meruelo D, Solomon A. Anti-angiogenic activities of hypericin in vivo: Potential for opthalmologic applications. Angiogenesis. 8: 35-42, 2005.

29. Weinberger D, Ron Y, Lusky M, Gaaton D, Orenstein A, Blank M, Mandel M, Livnat T, Barliya T, Lavie G. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Curr Eye Res. 30: 269-277, 2005.

30. Blank M, Lavie, G, Mandel M, Hazan S, Orenstein A, Keisari Y. Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer. 111: 596-603, 2004. In cover.

31. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced Hsp90 ubiquitinylation as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res. 63: 8241-8247, 2003.

32. Blank M, Kostenich G, Kimel S, Lavie G, Keisari Y, Orenstein A. Wavelength Dependent Properties of Photodynamic Therapy Using Hypericin in vitro and in an Animal Model. Photochem Photobiol. 76: 335-340, 2002.

33. Blank M, Mandel M, Hazan S, Keisari Y, Lavie G. Anti-cancer activities of hypericin in the dark. Photochem Photobiol. 74: 120-125, 2001.

34. Blank M, Lavie G, Mandel M, Keisari Y. Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res. 12: 409-418, 2000.